Next Article in Journal
Anti-Glycation Activities of Phenolic Constituents from Silybum marianum (Milk Thistle) Flower in Vitro and on Human Explants
Next Article in Special Issue
Can We Produce Heparin/Heparan Sulfate Biomimetics Using “Mother-Nature” as the Gold Standard?
Previous Article in Journal
Effect of Diterpenes Isolated of the Marine Alga Canistrocarpus cervicornis against Some Toxic Effects of the Venom of the Bothrops jararaca Snake
Previous Article in Special Issue
Diversity of Heparan Sulfate and HSV Entry: Basic Understanding and Treatment Strategies
Open AccessReview

Glycosaminoglycans and Glycomimetics in the Central Nervous System

John van Geest Centre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK
Proteoglycan Signaling and Therapeutics Research Group, Graduate School of Life Science, Faculty of Advanced Life Science, Hokkaido University, Sapporo 001-0021, Japan
Author to whom correspondence should be addressed.
Academic Editor: Vito Ferro
Molecules 2015, 20(3), 3527-3548;
Received: 22 January 2015 / Revised: 9 February 2015 / Accepted: 13 February 2015 / Published: 19 February 2015
(This article belongs to the Special Issue Glycosaminoglycans and Their Mimetics)
With recent advances in the construction of synthetic glycans, selective targeting of the extracellular matrix (ECM) as a potential treatment for a wide range of diseases has become increasingly popular. The use of compounds that mimic the structure or bioactive function of carbohydrate structures has been termed glycomimetics. These compounds are mostly synthetic glycans or glycan-binding constructs which manipulate cellular interactions. Glycosaminoglycans (GAGs) are major components of the ECM and exist as a diverse array of differentially sulphated disaccharide units. In the central nervous system (CNS), they are expressed by both neurons and glia and are crucial for brain development and brain homeostasis. The inherent diversity of GAGs make them an essential biological tool for regulating a complex range of cellular processes such as plasticity, cell interactions and inflammation. They are also involved in the pathologies of various neurological disorders, such as glial scar formation and psychiatric illnesses. It is this diversity of functions and potential for selective interventions which makes GAGs a tempting target. In this review, we shall describe the molecular make-up of GAGs and their incorporation into the ECM of the CNS. We shall highlight the different glycomimetic strategies that are currently being used in the nervous system. Finally, we shall discuss some possible targets in neurological disorders that may be addressed using glycomimetics. View Full-Text
Keywords: glycomimetics; glycosaminoglycans; central nervous system glycomimetics; glycosaminoglycans; central nervous system
MDPI and ACS Style

Rowlands, D.; Sugahara, K.; Kwok, J.C.F. Glycosaminoglycans and Glycomimetics in the Central Nervous System. Molecules 2015, 20, 3527-3548.

AMA Style

Rowlands D, Sugahara K, Kwok JCF. Glycosaminoglycans and Glycomimetics in the Central Nervous System. Molecules. 2015; 20(3):3527-3548.

Chicago/Turabian Style

Rowlands, Dáire; Sugahara, Kazuyuki; Kwok, Jessica C.F. 2015. "Glycosaminoglycans and Glycomimetics in the Central Nervous System" Molecules 20, no. 3: 3527-3548.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop